ISOFOL MEDICAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.694 SEK | -3.34% |
|
-5.45% | -4.93% |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 22.41M 2.05M | Sales 2022 | 12.8M 1.17M | Capitalization | 120M 10.93M |
|---|---|---|---|---|---|
| Net income 2021 | -200M -18.28M | Net income 2022 | -160M -14.63M | EV / Sales 2021 | 49.7 x |
| Net cash position 2021 | 378M 34.53M | Net cash position 2022 | 187M 17.06M | EV / Sales 2022 | -5.24 x |
| P/E ratio 2021 |
-5.8
x | P/E ratio 2022 |
-0.75
x | Employees | 3 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 62.57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.34% | ||
| 1 week | -5.45% | ||
| Current month | -10.10% | ||
| 1 month | -8.44% | ||
| 3 months | +3.27% | ||
| 6 months | -11.48% | ||
| Current year | -4.93% |
1 week
0.66
0.84
1 month
0.641.07
Current year
0.551.10
1 year
0.451.24
3 years
0.4517.00
5 years
0.4533.50
10 years
0.4533.50
| Managers | Title | Age | Since |
|---|---|---|---|
Petter Lindqvist
CEO | Chief Executive Officer | 72 | Jan. 08 |
Magnus Hurst
DFI | Director of Finance/CFO | 68 | Jan. 09 |
Roger Tell
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lars Erik Lind
CHM | Chairman | 83 | - |
Sten Nilsson
BRD | Director/Board Member | 76 | Jan. 03 |
Alain Herrera
BRD | Director/Board Member | 74 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.694 | -3.34% | 872,145 |
| 24-04-25 | 0.718 | +3.76% | 324,429 |
| 24-04-24 | 0.692 | -0.86% | 1,118,525 |
| 24-04-23 | 0.698 | -2.92% | 238,346 |
| 24-04-22 | 0.719 | -2.04% | 261,088 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:21 am EDT
More quotes
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Companyâs main shareholders are Biofol AB and Yield Life Science AB.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -4.93% | 10.63M | |
| +5.31% | 69.91B | |
| +10.97% | 9.03B | |
| -16.83% | 4.75B | |
| +43.48% | 4.31B | |
| +3.20% | 3.88B | |
| +18.82% | 2.37B | |
| -21.36% | 2.26B | |
| -29.67% | 2.2B | |
| +8.38% | 1.98B |
- Stock Market
- Equities
- ISOFOL Stock
